Literature DB >> 3933327

Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung.

R Komaki, J D Cox, A J Hartz, R W Byhardt, C Perez-Tamayo, L Clowry, H Choi, F Wilson, A Lopes da Conceicao, N Rangala.   

Abstract

Between January, 1971 and August, 1978, 410 patients with histologically or cytologically confirmed inoperable or unresectable carcinoma of the lung of all cell types were treated with curative intent. Forty-five patients lived a minimum of 3 years and 32 patients lived 5 or more years. The 3-year survival rate increased from 7.6% (15/197) between January, 1971 and June, 1975 to 14.1% (30/213) for the interval from July, 1975 to August, 1978 (p less than 0.01). Factors associated with long-term survival were performance status (p less than 0.01), early stage (p less than 0.001), high total dose of radiation (p less than 0.02), large cell carcinoma (p less than 0.01), inoperable for medical reasons (p less than 0.001), and thoracotomy to determine unresectability (p less than 0.04). The difference in survival rates between the two time periods was not related to different patient factors. Survival rates were most improved in the second time period for patients with Stage II or Stage III carcinoma of the lung. Eight patients died from cancer between 36 and 54 months of initial treatment. Five patients died of intercurrent disease without evidence of cancer of the lung after 3 years. An increasing proportion of long-term survivors of inoperable carcinoma of the lung can be expected to result from a better understanding of these diseases, more technically sophisticated external irradiation, and the use of combination chemotherapy for small cell carcinoma.

Entities:  

Mesh:

Year:  1985        PMID: 3933327     DOI: 10.1097/00000421-198510000-00005

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group.

Authors:  M F Muers; C E Round
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

2.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

Authors:  S M Eschmann; G Friedel; F Paulsen; M Reimold; T Hehr; W Budach; J Scheiderbauer; H J Machulla; H Dittmann; R Vonthein; R Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-04       Impact factor: 9.236

3.  Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Authors:  Dong Xie; Mark S Allen; Randolph Marks; Gening Jiang; Zhifu Sun; Frances Nichols; Mingrui Zhang; Chang Chen; Marie-Christine Aubry; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Dennis Wigle; Julian Molina; Claude Deschamps; Ping Yang
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

4.  18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.

Authors:  Susanne Martina Eschmann; Godehard Friedel; Frank Paulsen; Matthias Reimold; Thomas Hehr; Wilfried Budach; Heinz-Jakob Langen; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-14       Impact factor: 9.236

5.  Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

Review 6.  Assays for predicting and monitoring responses to lung cancer immunotherapy.

Authors:  Cristina Teixidó; Niki Karachaliou; Maria González-Cao; Daniela Morales-Espinosa; Rafael Rosell
Journal:  Cancer Biol Med       Date:  2015-06       Impact factor: 4.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.